A Non-severe Coronavirus Disease 2019 Patient With Persistently High Interleukin-6 Level

Frontiers in Public Health

article

Nurfarah Lydia Hambali¹  Benny O. Manin¹  Malehah Mohd Noh²  Shahleni Paramasivam²  Tock Hing Chua¹  Firdaus Hayati³  Alvin Oliver Payus²  Tze Yuan Tee⁴  Khairul Taufiq Rosli⁴  Mohammad Faruq Abd Rachman Isnadi¹ 

[1] Department of Pathobiology and Medical Diagnostic, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah;Medical Based Department, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah;Surgical Based Department, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah;Medical Department, Tawau Hospital

关键词: COVID-19;    cytokine release syndrome;    IL-6;    HBV infection;    HCC;   

DOI  :  10.3389/fpubh.2020.584552

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Interleukin 6 (IL-6) is one of the markers of immune system activation indicating existent infection and inflammation. We present here a case of a 55-year-old male COVID-19 patient with an unusual high level of interleukin 6 (IL-6). Further investigation revealed he had hepatocellular carcinoma (HCC) with underlying hepatitis B. He did not present with respiratory symptoms although a baseline chest x-ray showed changes, and the patient was categorized as Class 3A of COVID-19. Routine investigations proceeded with high-resolution computed tomography and IL-6 to monitor for progression to severe COVID-19. Notably, there was a high IL-6 level but other parameters did not show he was in severe COVID-19. In this report, we conclude that elevated IL-6 level in a COVID-19 patient is not necessarily associated with severe COVID-19.

【 授权许可】

CC BY